| Date Filed | Type | Description |
| 08/01/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Quarterly results |
| 02/27/2023 |
SC 13G/A
| SHORT JAY M PHD reports a 6.4% stake in BioAtla, Inc. |
| 02/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"BioAtla Announces Change in Executive Leadership SAN DIEGO, February 27, 2023 - BioAtla, Inc. , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as Chief Executive Officer at Viatris , a large, global healthcare pharmaceutical company. Scott will continue his relationship with BioAtla by serving as a Board of Directors member for the Company. “We extend our sincere thanks to Scott for his important contributions since joining the Company in 2018 and wish him well in his new endeavor,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla. “Sco..." |
|
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 8.6% stake in BioAtla, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8% stake in BioAtla, Inc. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/09/2023 |
SC 13D/A
| Soleus Private Equity Fund I, L.P. reports a 9.2% stake in BioAtla, Inc. |
| 01/06/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 01/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 01/06/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 11/07/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/04/2022 |
8-K
| Investor presentation |
| 11/04/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/21/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/06/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/04/2022 |
8-K
| Quarterly results |
|